Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T17:22:27.056Z.
Calculation as of: 2026-10-06T17:22:27.056Z.
Quote observation: 2026-10-06T17:18:37.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 00b46e2a658eb37d32f3c4bb775d4183c2cde6b20987a1f72f3e7425ee882fe4
PE RATIO
N/A
Market Cap
$155.86M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$158.60M
PE Ratio
N/A
TTM Avg
4.03
3Y Avg
4.03
5Y Avg
14.59
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LifeMD, Inc. (LFMDP) | $155.81M | N/A | N/A | N/A | N/A |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $155.86M | N/A | N/A | N/A | N/A |
| Neuronetics, Inc. (STIM)vs › | $156.17M | N/A | N/A | N/A | N/A |
| Inogen, Inc. (INGN)vs › | $156.76M | N/A | 65.68 | 52.50 | 80.75 |
| Minerva Neurosciences, Inc. (NERV)vs › | $158.60M | N/A | 4.03 | 4.03 | 14.59 |
| Coherus Oncology, Inc. (CHRS)vs › | $159.14M | N/A | 5.36 | 5.36 | 8.25 |
| PepGen Inc. (PEPG)vs › | $160.35M | N/A | N/A | N/A | N/A |
| ALX Oncology Holdings Inc. (ALXO)vs › | $150.71M | N/A | N/A | N/A | N/A |
| Cardiol Therapeutics Inc. (CRDL)vs › | $150.43M | N/A | N/A | N/A | N/A |
| Codexis, Inc. (CDXS)vs › | $149.51M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$22.85
Forward EPS (Est.)
$-0.52
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
